Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.375 GBX | -0.57% | -18.60% | -46.15% |
Apr. 24 | Genedrive enters clinical trial deal in US for MT-RNR1 US approval | AN |
Apr. 03 | FTSE 100 up thanks to US economic data | AN |
Sales 2022 | 49K 61.47K | Sales 2023 | 55K 68.99K | Capitalization | 17.33M 21.74M |
---|---|---|---|---|---|
Net income 2022 | -4M -5.02M | Net income 2023 | -5M -6.27M | EV / Sales 2022 | 237 x |
Net cash position 2022 | 4.57M 5.74M | Net cash position 2023 | 2.36M 2.96M | EV / Sales 2023 | 272 x |
P/E ratio 2022 |
-3.18
x | P/E ratio 2023 |
-3.18
x | Employees | 43 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 47.93% |
1 day | -0.57% | ||
1 week | -18.60% | ||
Current month | -14.63% | ||
1 month | -43.91% | ||
3 months | -32.69% | ||
6 months | -50.70% | ||
Current year | -46.15% |
Managers | Title | Age | Since |
---|---|---|---|
James Cheek
CEO | Chief Executive Officer | 57 | 23-09-10 |
Russell Shaw
DFI | Director of Finance/CFO | 45 | 22-04-06 |
Ian Gilham
CHM | Chairman | 64 | 14-11-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ian Gilham
CHM | Chairman | 64 | 14-11-23 |
Chris Yates
BRD | Director/Board Member | 50 | 18-08-21 |
Thomas Lindsay
BRD | Director/Board Member | 66 | 18-04-08 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 4.375 | -0.57% | 2,228,811 |
24-05-02 | 4.4 | -9.74% | 2,703,832 |
24-05-01 | 4.875 | -4.88% | 630,501 |
24-04-30 | 5.125 | +2.50% | 2,012,090 |
24-04-29 | 5 | -6.98% | 506,281 |
Delayed Quote London S.E., May 03, 2024 at 11:35 am EDT
More quotesChiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-46.15% | 7.86M | |
-14.68% | 18.88B | |
-42.33% | 2.84B | |
+17.00% | 1.85B | |
-0.51% | 1.66B | |
+27.15% | 1.26B | |
-13.90% | 989M | |
-21.76% | 896M | |
-2.72% | 757M | |
-23.95% | 637M |
- Stock Market
- Equities
- EHP Stock